Clinical Trial Update: Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 study assessing tolerability and efficacy of a ribavirin-free regimen of grazoprevir and elbasvir for 12 weeks in patients with chronic hepatitis C geno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Hepatitis C, Compensated Cirrhosis | Phase 3 | Status: UNKNOWN